| Alpha rhythm...................................................................................................31 |
| Antioxidant effect..............................................................................................9 |
| Benign familial infantile epilepsy..................................................................121 |
| Biomarker........................................................................................................37 |
| CADASIL........................................................................................................34 |
| Cardiac conduction disorders.........................................................................105 |
| Cardiac side effect..........................................................................................105 |
| Children............................................................................................................26 |
| Cognitive functions..........................................................................................16 |
| Collective ground sports....................................................................................1 |
| Complete blood parameter indices...................................................................75 |
| Confusional arousal.........................................................................................62 |
| COVID-19 vaccination....................................................................................50 |
| Diagnosis..........................................................................................................56 |
| Digital neuropsychology..................................................................................16 |
| Electrocardiography.......................................................................................105 |
| Electroencephalography...................................................................................26 |
| Engel classification........................................................................................115 |
| Epilepsy................................................1, 26, 37, 46, 50, 56, 75, 79, 83, 96, 126 |
| Epilepsy Disease Concealment Scale..............................................................83 |
| Epilepsy surgery.............................................................................................115 |
| Epileptic paroxysmal arousal...........................................................................62 |
| Focal epileptic seizure......................................................................................34 |
| Fucose..............................................................................................................41 |
| GAERS............................................................................................................69 |
| Gene expression...............................................................................................96 |
| Generalized non-reactive alpha activity...........................................................31 |
| Grey zone.........................................................................................................31 |
| Gymnastic..........................................................................................................1 |
| Hepatotoxicity....................................................................................................9 |
| Hexosamine......................................................................................................41 |
| Hexose..............................................................................................................41 |
| Hyperoxia.........................................................................................................96 |
| Hypothyroidism...............................................................................................46 |
| Idiopathic generalized epilepsy........................................................................16 |
| Inflammation..............................................................................................75, 79 |
| Juvenile myoclonic epilepsy............................................................................87 |
| Lamotrigine....................................................................................................105 |
| Levetiracetam...................................................................................................69 |
| Long-term EEG................................................................................................91 |
| Martial arts.........................................................................................................1 |
| Maternal behavior............................................................................................69 |
| Moringa............................................................................................................41 |
| Neonatal hyperoxia..........................................................................................96 |
| Neurology......................................................................................................105 |
| Neuropsychological evaluation........................................................................87 |
| Nociception....................................................................................................126 |
| Non-convulsive status epilepticus....................................................................31 |
| NOTCH3 gene..................................................................................................34 |
| NREM parasomnias.........................................................................................62 |
| Outdoor sports....................................................................................................1 |
| Oxidative stress..................................................................................................9 |
| Paroxysmal kinesigenic dyskinesia................................................................121 |
| Pfizer biontech.................................................................................................50 |
| Physical exercise................................................................................................1 |
| Platelet..............................................................................................................75 |
| Polytherapy......................................................................................................46 |
| Pregnancy.............................................................................................69, 75, 79 |
| PRRT2............................................................................................................121 |
| Quality of Life Scale in Patients with Epilepsy...............................................83 |
| Relatives.........................................................................................................111 |
| Routine EEG....................................................................................................91 |
| S100B...............................................................................................................37 |
| Salzburg criteria...............................................................................................31 |
| Seizure risk.....................................................................................................111 |
| Seizure-free......................................................................................................91 |
| Sialic acid.........................................................................................................41 |
| Side effect................................................................................................50, 126 |
| Sinovac-coronavac...........................................................................................50 |
| Sleep-related hypermotor epilepsy..................................................................62 |
| Sports.................................................................................................................1 |
| Status epilepticus.............................................................................................21 |
| Status epilepticus etiology...............................................................................21 |
| Status epilepticus in-hospital mortality............................................................21 |
| Stigma..............................................................................................................83 |
| Stomach............................................................................................................41 |
| Sudden unexpected death in epilepsy............................................................111 |
| Survey............................................................................................................111 |
| Synaptopathy..................................................................................................121 |
| Temporal lobe epilepsy..................................................................................115 |
| Trigeminal pain..............................................................................................126 |
| Vagus nerve stimulation.................................................................................126 |
| Valproic acid..........................................................................................9, 41, 69 |
| Video-EEG monitoring....................................................................................56 |
| Video-electroencephalography.........................................................................56 |
| Visual spatial functions....................................................................................87 |
| Vitamin b6..........................................................................................................9 |